Elite Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is April - March.

Millions USD. Fiscal year is Apr - Mar.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022	Mar '21 Mar 31, 2021
Cash & Equivalents	21.09	11.32	7.11	7.83	8.54	3.19
Cash & Short-Term Investments	21.09	11.32	7.11	7.83	8.54	3.19
Cash Growth	154.37%	59.23%	-9.27%	-8.24%	167.33%	182.11%
Receivables	48.53	29.21	19.45	3.09	3.06	3.5
Inventory	25.1	16.24	12.93	9.55	6.74	5.01
Prepaid Expenses	2.07	0.98	0.52	1.03	0.53	0.49
Total Current Assets	96.79	57.74	40.01	21.51	18.86	12.19
Property, Plant & Equipment	13.1	14.1	14.61	10.44	6.98	6.86
Other Intangible Assets	0.29	0.29	0.29	0.29	0.47	0.47
Long-Term Deferred Tax Assets	10.33	18.37	22.16	2.17	2.17	-
Long-Term Deferred Charges	5.35	5.35	6.05	6.05	6.17	6.17
Other Long-Term Assets	0.56	0.55	0.53	0.43	0.5	0.5
Total Assets	126.41	96.39	83.65	40.9	35.15	26.19
Accounts Payable	6.52	2.96	2.71	2.45	1.43	0.93
Accrued Expenses	4.75	3.45	4.82	4.63	4.28	4.27
Short-Term Debt	-	4	4	-	-	-
Current Portion of Long-Term Debt	0.23	0.25	0.3	0.31	0.35	0.41
Current Portion of Leases	0.89	0.84	0.72	0.01	0.2	0.19
Current Income Taxes Payable	0.8	0.34	0.49	0.41	0.41	-
Current Unearned Revenue	-	0.01	0.01	0.01	0.01	0.01
Total Current Liabilities	13.19	11.84	13.05	7.83	6.69	5.81
Long-Term Debt	2.82	3.03	3.28	3.56	1.39	1.74
Long-Term Leases	2.11	2.8	3.44	-	0.84	0.04
Long-Term Unearned Revenue	-	-	0.01	0.02	0.03	0.05
Other Long-Term Liabilities	27.97	25.2	6.3	0.52	0.98	2.4
Total Liabilities	46.1	42.87	26.07	11.94	9.93	10.04
Common Stock	1.07	1.07	1.07	1.01	1.01	1.01
Additional Paid-In Capital	173.84	173.46	173.21	164.75	164.58	164.41
Retained Earnings	-94.29	-120.7	-116.39	-136.5	-140.06	-148.96
Treasury Stock	-0.31	-0.31	-0.31	-0.31	-0.31	-0.31
Total Common Equity	80.31	53.52	57.58	28.96	25.22	16.15
Shareholders' Equity	80.31	53.52	57.58	28.96	25.22	16.15
Total Liabilities & Equity	126.41	96.39	83.65	40.9	35.15	26.19
Total Debt	6.06	10.91	11.74	3.89	2.78	2.38
Net Cash (Debt)	15.04	0.4	-4.63	3.94	5.75	0.81
Net Cash Growth	-	-	-	-31.44%	606.63%	-
Net Cash Per Share	0.01	0.00	-0.00	0.00	0.01	0.00
Filing Date Shares Outstanding	1,077	1,068	1,068	1,014	1,011	1,009
Total Common Shares Outstanding	1,074	1,068	1,068	1,014	1,011	1,009
Working Capital	83.6	45.9	26.96	13.68	12.17	6.38
Book Value Per Share	0.07	0.05	0.05	0.03	0.02	0.02
Tangible Book Value	80.03	53.23	57.29	28.67	24.76	15.69
Tangible Book Value Per Share	0.07	0.05	0.05	0.03	0.02	0.02
Land	11.65	11.65	11.06	10.77	5.46	5.46
Machinery	16.23	15.71	15.02	14.24	13.85	13.35

Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.